Marker Therapeutics Announces Clinical Program Updates and

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical...

Related Keywords

Baylor College Of Medicine ,Texas ,United States ,Houston ,Juan Vera ,Casey Mcdonald ,Daniel Kontoh Boateng ,Drug Administration ,Cell Ready Press ,Nasdaq ,Marker Therapeutics Inc ,Cell Ready ,Press Release ,Previous Clinical ,Baylor College ,Pre Clinical Data ,Company Sponsored Phase ,Clinical Observations ,New Directions ,Investigational New Drug ,Marker Therapeutics ,Private Securities Litigation Reform Act ,Nasdaq Mrkr ,Wrkr ,